Patents Assigned to Guangzhou Innocare Pharma Tech Co., Ltd.
  • Substituted nicotinimide inhibitors of BTK for treating cancer
    Patent number: 11840513
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: December 12, 2023
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni
  • Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
    Patent number: 11345695
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: May 31, 2022
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill
  • Heterocyclic compounds as FGFR inhibitors
    Patent number: 10752631
    Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and a use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, a prodrug, a solvate, a polymorph, an isomer, or a stable isotopic derivative thereof. The present invention further relates to a method of treating or preventing a FGFR-mediated disease, such as cancer, using the compound.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 25, 2020
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Norman Xianglong Kong, Chao Zhou, Xiangyang Chen
  • HETEROCYCLIC COMPOUNDS AS FGFR INHIBITOR
    Publication number: 20190177333
    Abstract: The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and a use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, a prodrug, a solvate, a polymorph, an isomer, or a stable isotopic derivative thereof. The present invention further relates to a method of treating or preventing a FGFR-mediated disease, such as cancer, using the compound.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 13, 2019
    Applicant: GUANGZHOU INNOCARE PHARMA TECH CO., LTD.
    Inventors: Norman Xianglong KONG, Chao ZHOU, Xiangyang CHEN
  • Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
    Patent number: 10301297
    Abstract: Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: May 28, 2019
    Assignee: Guangzhou Innocare Pharma Tech Co., Ltd.
    Inventors: Xiangyang Chen, Yingxiang Gao, Chong Liu, Haihong Ni, Mark Mulvihill